{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:59:52Z","timestamp":1790351992564,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arena Life Science company","award":["30245"],"award-info":[{"award-number":["30245"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lichen planus (LP) is a chronic autoimmune inflammatory disorder with limited effective long-term treatment options. Hydroxychloroquine has been widely used as systemic therapy, and although baricitinib, a Janus kinase 1\/2 inhibitor, has shown promise in patients with refractory cases, comparative evidence is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to compare the efficacy and safety of baricitinib vs. hydroxychloroquine in patients with cutaneous LP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized controlled trial, 32 patients with cutaneous LP were randomized to baricitinib 4\u2005mg once daily or hydroxychloroquine 200\u2005mg twice daily for 12 weeks. The primary outcome was the change in Lichen Planus Activity and Damage Index (LiPADI). Secondary outcomes included pruritus severity, patient satisfaction (each assessed using a 0\u201310 visual analogue scale) and Physician Global Assessment (PGA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both groups showed significant improvement in pruritus severity and LiPADI scores (P &amp;lt; 0.001). Mean LiPADI scores decreased from 14.20 (SD 3.44) to 1.07 (SD 0.99) with baricitinib and from 12.18 (SD 3.28) to 5.27 (SD 2.28) with hydroxychloroquine (P = 0.03), indicating a greater reduction in disease activity with baricitinib. The pruritus visual analogue scale improved from 8.33 (SD 1.67) to 0.21 (SD 0.80) in the baricitinib group and from 8.81 (SD 1.66) to 3.27 (SD 1.01) in the hydroxychloroquine group (P &amp;lt; 0.001). Patient satisfaction increased from 4.46 (SD 0.83) to 8.78 (SD 1.12) and from 4.63 (SD 0.50) to 6.90 (SD 0.94), respectively (P = 0.001). PGA improved in both groups, but the between-group difference was not statistically significant (P = 0.38). No major or life-threatening adverse events were observed in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this assessor-blinded randomized trial, both baricitinib and hydroxychloroquine improved cutaneous LP over 12 weeks. Baricitinib was associated with greater short-term improvement in disease activity and pruritus, along with higher patient satisfaction, without evidence of additional short-term safety concerns. The small sample size, short follow-up and nondouble-blind design warrant cautious interpretation. Large double-blind studies with longer follow-up are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag210","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:46:59Z","timestamp":1779277619000},"page":"1865-1873","source":"Crossref","is-referenced-by-count":0,"title":["Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9946-9883","authenticated-orcid":false,"given":"Hossein","family":"Kargar","sequence":"first","affiliation":[{"name":"Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences , Shiraz ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-5107","authenticated-orcid":false,"given":"Mohammad Ali","family":"Esfandiari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences , Shiraz ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-1988","authenticated-orcid":false,"given":"Mehdi","family":"Ghahartars","sequence":"additional","affiliation":[{"name":"Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences , Shiraz ,","place":["Iran"]},{"name":"Molecular Dermatology Research Center, Shiraz University of Medical Sciences , Shiraz ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-945X","authenticated-orcid":false,"given":"Mohammad Mahdi","family":"Parvizi","sequence":"additional","affiliation":[{"name":"Molecular Dermatology Research Center, Shiraz University of Medical Sciences , Shiraz ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026092511031179100_llag210-B1","volume-title":"Andrews\u2019 Diseases of the Skin: Clinical Dermatology","author":"James","year":"2024","edition":"14th edn"},{"key":"2026092511031179100_llag210-B2","doi-asserted-by":"crossref","first-page":"737813","DOI":"10.3389\/fmed.2021.737813","article-title":"Lichen planus","volume":"8","author":"Boch","year":"2021","journal-title":"Front Med"},{"key":"2026092511031179100_llag210-B3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijd.13806","article-title":"Lichen planus pigmentosus and its variants: review and update","volume":"57","author":"Robles-M\u00e9ndez","year":"2018","journal-title":"Int J Dermatol"},{"key":"2026092511031179100_llag210-B4","first-page":"523","article-title":"Assessment of griseofulvin in the management of lichen planus","volume":"3","author":"Parmar","year":"2017","journal-title":"Int J Res"},{"key":"2026092511031179100_llag210-B5","volume-title":"UpToDate","author":"Goldstein","year":"2019"},{"key":"2026092511031179100_llag210-B6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jaad.2018.02.010","article-title":"Lichen planus and lichenoid dermatoses: clinical overview and molecular basis","volume":"79","author":"Tziotzios","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026092511031179100_llag210-B7","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1021\/acs.cgd.2c00156","article-title":"Polymorphism in griseofulvin: new story between an old drug and polyethylene glycol","volume":"22","author":"Ou","year":"2022","journal-title":"Crystal Growth Design"},{"key":"2026092511031179100_llag210-B8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/09546634.2018.1544411","article-title":"Treatment of cutaneous lichen planus (part 2): a review of systemic therapies","volume":"30","author":"Thandar","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"2026092511031179100_llag210-B9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/odi.12634","article-title":"Interventions for the management of oral lichen planus: a review of the conventional and novel therapies","volume":"23","author":"Gupta","year":"2017","journal-title":"Oral Dis"},{"key":"2026092511031179100_llag210-B10","volume-title":"Comprehensive Dermatologic Drug Therapy","author":"Wolverton","year":"2019"},{"key":"2026092511031179100_llag210-B11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00403-016-1667-2","article-title":"Oral lichen planus: a literature review and update","volume":"308","author":"Alrashdan","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"2026092511031179100_llag210-B12","first-page":"1","article-title":"Multi-drug induced palmar and plantar lichen planus: first description in the medical literature","volume":"6","author":"Tchernev","year":"2019","journal-title":"Clin Res Dermatol Open Access"},{"key":"2026092511031179100_llag210-B13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40257-024-00878-9","article-title":"Lichen planus: what is new in \u00addiagnosis and treatment?","volume":"25","author":"Tekin","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026092511031179100_llag210-B14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ad.2012.10.005","article-title":"Antimalarials in dermatology: mechanism of action, indications and side effects","volume":"105","author":"Rodriguez-Caruncho","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"2026092511031179100_llag210-B15","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1111\/ajd.13168","article-title":"Hydroxychloroquine in dermatology: new perspectives on an old drug","volume":"61","author":"Chew","year":"2020","journal-title":"Australas J Dermatol"},{"key":"2026092511031179100_llag210-B16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jdin.2024.02.008","article-title":"Effectiveness and tolerability of systemic therapies in oral lichen planus: a retrospective cohort study","volume":"15","author":"Myers","year":"2024","journal-title":"JAAD Int"},{"key":"2026092511031179100_llag210-B17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00403-025-04226-7","article-title":"Hydroxychloroquine is safe and efficacious in oral lichen planus: data from a large outpatient cohort","volume":"317","author":"Abdusalamova","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"2026092511031179100_llag210-B18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.oooo.2023.12.007","article-title":"Hydroxychloroquine for the management of recalcitrant oral lichen planus","volume":"137","author":"Chirravur","year":"2024","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"2026092511031179100_llag210-B19","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/09546634.2022.2116926","article-title":"JAK inhibitors in lichen planus: a review of pathogenesis and treatments","volume":"33","author":"Motamed-Sanaye","year":"2022","journal-title":"J Dermatol Treat"},{"key":"2026092511031179100_llag210-B20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026092511031179100_llag210-B21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026092511031179100_llag210-B22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/12034754231156100","article-title":"The use of Janus kinase inhibitors for lichen planus: an evidence-based review","volume":"27","author":"Abduelmula","year":"2023","journal-title":"J Cut Med Surg"},{"key":"2026092511031179100_llag210-B23","doi-asserted-by":"crossref","first-page":"e179436","DOI":"10.1172\/JCI179436","article-title":"Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13","volume":"135","author":"Hwang","year":"2024","journal-title":"J Clin Invest"},{"key":"2026092511031179100_llag210-B24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jclinepi.2010.02.005","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Schulz","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2026092511031179100_llag210-B25","doi-asserted-by":"crossref","first-page":"e13578","DOI":"10.1111\/dth.13578","article-title":"Comparison of therapeutic efficacy of topical treatment with phenytoin and fluocinolone on cutaneous lichen planus: a randomized, double-blind trial","volume":"33","author":"Sepaskhah","year":"2020","journal-title":"Dermatol Ther"},{"key":"2026092511031179100_llag210-B26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/medicina61061056","article-title":"Use of JAK inhibitors in lichen planus: an update","volume":"61","author":"Didona","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"2026092511031179100_llag210-B27","doi-asserted-by":"publisher","author":"Hwang","DOI":"10.1101\/2024.01.09.24300946"},{"key":"2026092511031179100_llag210-B28","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.2174\/1381612826666200707132920","article-title":"The role of chloroquine and hydroxychloroquine in immune regulation and diseases","volume":"26","author":"Martinez","year":"2020","journal-title":"Curr Pharm Des"},{"key":"2026092511031179100_llag210-B29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0190-9622(93)70082-5","article-title":"Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial","volume":"28","author":"Eisen","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"2026092511031179100_llag210-B30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak pruritus \u00adnumerical rating scale: psychometric validation and responder \u00addefinition for assessing itch in moderate-to-severe atopic \u00addermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag210\/68347883\/llag210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1865\/68347883\/llag210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1865\/68347883\/llag210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:03:24Z","timestamp":1790348604000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/10\/1865\/8688394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5,20]]},"published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag210","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,20]]}}}